<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00368992</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02903</org_study_id>
    <secondary_id>S0536</secondary_id>
    <secondary_id>U10CA032102</secondary_id>
    <nct_id>NCT00368992</nct_id>
  </id_info>
  <brief_title>S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed By Cetuximab and Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Monoclonal antibodies, such as cetuximab and bevacizumab, can block tumor growth in different
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
      help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth
      of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab may stop
      the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy,
      such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells,
      either by killing the cells or by stopping them from dividing. Giving cetuximab together with
      paclitaxel, carboplatin, and bevacizumab may kill more tumor cells. This phase II trial is
      studying how well giving cetuximab together with paclitaxel, carboplatin, and bevacizumab
      works in treating patients with advanced non-small cell lung cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the frequency and severity of hemorrhage toxicities in patients with advanced
      non-small cell lung cancer treated with the combination of carboplatin, paclitaxel, cetuximab
      and bevacizumab followed by therapy with cetuximab and bevacizumab.

      SECONDARY OBJECTIVES:

      I. To evaluate progression-free and overall survival, response rate (confirmed plus
      unconfirmed, complete plus partial), and frequency and severity of non-hemorrhage toxicities
      in this group of patients treated with this regimen.

      II. To perform molecular correlative studies on patient tissue to investigate in an
      exploratory manner potential predictors of efficacy.

      OUTLINE: This is a multicenter study.

      INDUCTION THERAPY: Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and
      paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90
      minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of
      disease progression or unacceptable toxicity.

      MAINTENANCE THERAPY: Patients receive cetuximab IV over 1 hour on days 1, 8, and 15 and
      bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of
      disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed every 3 months for 1 year and then
      every 6 months for up to 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Patients With Grade 4 (i.e. Life-threatening) Hemorrhage Toxicities Related to Protocol Treatment.</measure>
    <time_frame>Every week until removed from protocol therapy, up to 3 years.</time_frame>
    <description>All patients who received protocol treatment were assessed for adverse events per the NCI Common Terminology Criteria for Adverse Events, Version 3.0. We counted the number of patients who reported at least one Grade 4 (i.e. life-threatening) hemorrhage adverse event that was possibly, probably, or definitely related to the study treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>Every 6 weeks until disease progression. After 9 months, every 12 weeks until disease progression, up to 3 years.</time_frame>
    <description>From data of registration to date of disease progression (as defined by RECIST, i.e. a 20% increase in the sum of the longest diameters of target lesions, or unequivocal progression ina non-target lesion in the opinion of the treating investigator, or the appearance of new lesions), symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free were censored at the date of last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Once a week, up to 3 years.</time_frame>
    <description>From date of enrollment to date of death due to any cause. Patients last known to be alive were censored at date of last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Every 6 weeks while on protocol treatment, up to 3 years.</time_frame>
    <description>Confirmed and unconfirmed complete and partial responses per RECIST in the subset of patients with at least one target lesion assessed by CT or MRI. A complete response (CR) was defined as disappearance of all disease, including non-target lesions. A partial response (PR) was defined as a &gt;= 30% decrease in the sum of the longest diameters of all target lesions. A CR or PR was confirmed if documented a second time at least 4 weeks after the first documentation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Adenocarcinoma of the Lung</condition>
  <condition>Adenosquamous Cell Lung Cancer</condition>
  <condition>Bronchoalveolar Cell Lung Cancer</condition>
  <condition>Large Cell Lung Cancer</condition>
  <condition>Recurrent Non-small Cell Lung Cancer</condition>
  <condition>Squamous Cell Lung Cancer</condition>
  <condition>Stage IIIB Non-small Cell Lung Cancer</condition>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (cetuximab, paclitaxel, bevacizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INDUCTION THERAPY: Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive cetuximab IV over 1 hour on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (cetuximab, paclitaxel, bevacizumab)</arm_group_label>
    <other_name>C225</other_name>
    <other_name>C225 monoclonal antibody</other_name>
    <other_name>IMC-C225</other_name>
    <other_name>MOAB C225</other_name>
    <other_name>monoclonal antibody C225</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (cetuximab, paclitaxel, bevacizumab)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (cetuximab, paclitaxel, bevacizumab)</arm_group_label>
    <other_name>anti-VEGF humanized monoclonal antibody</other_name>
    <other_name>anti-VEGF monoclonal antibody</other_name>
    <other_name>Avastin</other_name>
    <other_name>rhuMAb VEGF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically proven newly diagnosed selected
             stage IIIB (T4 lesion due to malignant pleural effusion) or stage IV, advanced primary
             non-small cell lung cancer (adenocarcinoma, large cell carcinoma, or unspecified) or
             recurrent disease after previous surgery and/or irradiation; patients with tumors
             having squamous cell components &gt; 50% are not eligible

          -  Patients with known brain metastases are not eligible; all patients must have a
             pretreatment CT or MRI scan of the brain to evaluate for CNS disease within 42 days
             prior to registration

          -  Patients may have measurable or non-measurable disease documented by CT, MRI, X-ray or
             physical exam; measurable disease must be assessed within 28 days prior to
             registration; pleural effusions, ascites and laboratory parameters are not acceptable
             as the only evidence of disease; non-measurable disease must be assessed within 42
             days prior to registration; all disease must be assessed and documented on the
             Baseline Tumor Assessment Form (Form #848)

          -  Patients must not have received any prior systemic chemotherapy or biologic therapy
             for non-small cell lung cancer; patients must not have received any adjuvant therapy
             for non-small cell lung cancer

          -  Prior radiation is permitted; however, at least three weeks must have elapsed since
             the completion of prior radiation therapy and patients must have recovered from all
             associated toxicities at time of registration; measurable or non-measurable disease
             must be outside the previous radiation field or a new lesion must be present

          -  At least four weeks must have elapsed since surgery (thoracic or other major
             surgeries) and patients must have recovered from all associated toxicities at the time
             of registration; measurable disease must be present outside the area of surgical
             resection; there must be no anticipation of need for major surgical procedures during
             protocol treatment

          -  Patients must not have received prior cetuximab, ZD1839, erlotinib or other
             investigational agents that target the EGFR pathway; patients must not have received
             prior VEGF-related agents; patients must not have received prior chimerized or murine
             monoclonal antibody therapy or have documented presence of human anti-mouse antibodies
             (HAMA)

          -  ANC &gt;= 1,500/mcl

          -  Platelet count &gt;= 100,000/mcl

          -  Hemoglobin &gt;= 9 mg/dl

          -  Patients must have a serum creatinine =&lt; institutional upper limit of normal (IULN)
             AND calculated or measured creatinine clearance &gt;= 50 cc/min using the Cockroft-Gault
             Formula

          -  Urine protein must be screened by urine analysis for Urine Protein Creatinine (UPC)
             ratio; for UPC ratio &gt; 0.5, 24-hour urine protein must be obtained and the level must
             be &lt; 1,000 mg for patient enrollment

          -  Serum bilirubin =&lt; 2 x IULN

          -  Either SGOT or SGPT =&lt; 2 x IULN (if both SGOT and SGPT are done, both must be =&lt; 2 x
             IULN)

          -  International Normalized Ratio (INR) =&lt; 1.5; patients must not be taking full-dose
             anticoagulation therapy; patients may be enrolled initially if they are on low-dose
             warfarin (i.e., 1 mg daily)

          -  All patients must have a Zubrod performance status of 0 - 1

          -  Correlative science studies: institutions must have received IRB approval of S9925
             (the Lung Cancer Specimen Repository); patients must be offered participation in
             S9925; with the patient's consent, blood, plasma and tissue will be submitted for
             testing via S9925; patients must be registered separately to S9925 in order for
             institutions to receive credit for specimen submissions

          -  Patients must not have had hemoptysis &gt;= 1/2 teaspoon within 3 months prior to
             registration

          -  Patients must not have &gt;= grade 2 symptomatic neuropathy-sensory (National Cancer
             Institute [NCI] Common Terminology Criteria Version 3.0)

          -  Patients must not have documented evidence of acute hepatitis or have an active or
             uncontrolled infection

          -  Patients must not have the following: history (within past 6 months) of CVA,
             myocardial infarction or unstable angina; uncontrolled hypertension; New York Heart
             Association grade 2 or greater congestive heart failure; serious cardiac arrhythmia
             requiring medication; or clinically significant peripheral vascular disease

          -  Patients must not have had an open biopsy or significant traumatic injury within 28
             days prior to registration; patients must not have had a core biopsy within 7 days
             prior to registration

          -  Patients must not have serious or non-healing wound, ulcer or bone fracture

          -  Patients must not have history of abdominal fistula, gastrointestinal perforation or
             intraabdominal abscess within 28 days prior to registration

          -  Patients must have no known hypersensitivity of Chinese hamster ovary cell products or
             other recombinant human antibodies

          -  Patients must not have evidence of bleeding diathesis or coagulopathy

          -  Patients must be willing to provide prior smoking history as required on the S0536
             Prestudy Form (Form #54655)

          -  No other prior malignancy is allowed except for the following: adequately treated
             basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
             stage I or II cancer from which the patient is currently in complete remission, or any
             other cancer from which the patient has been disease-free for 5 years

          -  Pregnant or nursing women are not eligible for this trial; women/men of reproductive
             potential must not participate unless they have agreed to use an effective
             contraceptive method during protocol treatment and for at least 6 months following
             completion of bevacizumab treatment

          -  Patients must be informed of the investigational nature of this study and must sign
             and give written informed consent in accordance with institutional and federal
             guidelines

          -  At the time of patient registration, the treating institution's name and ID number
             must be provided to the Data Operations Center in Seattle in order to ensure that the
             current (within 365 days) date of institutional review board approval for this study
             has been entered into the data base
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southwest Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southwest Oncology Group</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2006</study_first_submitted>
  <study_first_submitted_qc>August 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2006</study_first_posted>
  <results_first_submitted>October 30, 2012</results_first_submitted>
  <results_first_submitted_qc>August 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 14, 2015</results_first_posted>
  <last_update_submitted>August 11, 2015</last_update_submitted>
  <last_update_submitted_qc>August 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma, Bronchiolo-Alveolar</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab</title>
          <description>This was a single arm Phase II trial. Patients were treated with induction therapy cetuximab IV over 1-2 hours on days 1, 8, and 15 and paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Patients who were not removed due to unacceptable toxicity or disease progression were then treated with maintenance therapy cetuximab IV over 1 hour on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused treatment</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab</title>
          <description>This was a single arm Phase II trial. Patients were treated until progression.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="42" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Patients With Grade 4 (i.e. Life-threatening) Hemorrhage Toxicities Related to Protocol Treatment.</title>
        <description>All patients who received protocol treatment were assessed for adverse events per the NCI Common Terminology Criteria for Adverse Events, Version 3.0. We counted the number of patients who reported at least one Grade 4 (i.e. life-threatening) hemorrhage adverse event that was possibly, probably, or definitely related to the study treatment.</description>
        <time_frame>Every week until removed from protocol therapy, up to 3 years.</time_frame>
        <population>Eligible patients who received protocol treatment were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab</title>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients With Grade 4 (i.e. Life-threatening) Hemorrhage Toxicities Related to Protocol Treatment.</title>
          <description>All patients who received protocol treatment were assessed for adverse events per the NCI Common Terminology Criteria for Adverse Events, Version 3.0. We counted the number of patients who reported at least one Grade 4 (i.e. life-threatening) hemorrhage adverse event that was possibly, probably, or definitely related to the study treatment.</description>
          <population>Eligible patients who received protocol treatment were included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival</title>
        <description>From data of registration to date of disease progression (as defined by RECIST, i.e. a 20% increase in the sum of the longest diameters of target lesions, or unequivocal progression ina non-target lesion in the opinion of the treating investigator, or the appearance of new lesions), symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free were censored at the date of last contact.</description>
        <time_frame>Every 6 weeks until disease progression. After 9 months, every 12 weeks until disease progression, up to 3 years.</time_frame>
        <population>Eligible patients who received protocol treatment were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab</title>
            <description>This was a single arm Phase II trial. Patients were treated until progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival</title>
          <description>From data of registration to date of disease progression (as defined by RECIST, i.e. a 20% increase in the sum of the longest diameters of target lesions, or unequivocal progression ina non-target lesion in the opinion of the treating investigator, or the appearance of new lesions), symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free were censored at the date of last contact.</description>
          <population>Eligible patients who received protocol treatment were included in the analysis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="6" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>From date of enrollment to date of death due to any cause. Patients last known to be alive were censored at date of last contact.</description>
        <time_frame>Once a week, up to 3 years.</time_frame>
        <population>Eligible patients who received protocol treatment were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab</title>
            <description>This was a single arm Phase II trial. Patients were treated until progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>From date of enrollment to date of death due to any cause. Patients last known to be alive were censored at date of last contact.</description>
          <population>Eligible patients who received protocol treatment were included in the analysis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="11" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate</title>
        <description>Confirmed and unconfirmed complete and partial responses per RECIST in the subset of patients with at least one target lesion assessed by CT or MRI. A complete response (CR) was defined as disappearance of all disease, including non-target lesions. A partial response (PR) was defined as a &gt;= 30% decrease in the sum of the longest diameters of all target lesions. A CR or PR was confirmed if documented a second time at least 4 weeks after the first documentation.</description>
        <time_frame>Every 6 weeks while on protocol treatment, up to 3 years.</time_frame>
        <population>Eligible patients who received protocol treatment and who had measurable disease (as defined by RECIST) at baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab</title>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Confirmed and unconfirmed complete and partial responses per RECIST in the subset of patients with at least one target lesion assessed by CT or MRI. A complete response (CR) was defined as disappearance of all disease, including non-target lesions. A partial response (PR) was defined as a &gt;= 30% decrease in the sum of the longest diameters of all target lesions. A CR or PR was confirmed if documented a second time at least 4 weeks after the first documentation.</description>
          <population>Eligible patients who received protocol treatment and who had measurable disease (as defined by RECIST) at baseline were included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="44" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Weekly while on protocol treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac-ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Left ventricular diastolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia - Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Gastritis (including bile reflux gastritis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam) - Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Obstruction, GI - Small bowel NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death not associated with CTCAE term - Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytokine release syndrome/acute infusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Inf (clin/microbio) w/Gr 3-4 neuts - Blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Inf (clin/microbio) w/Gr 3-4 neuts - Colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Inf (clin/microbio) w/Gr 3-4 neuts - Lung</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Inf (clin/microbio) w/Gr 3-4 neuts - Sinus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Inf (clin/microbio) w/Gr 3-4 neuts - UTI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Inf w/normal ANC or Gr 1-2 neutrophils - Blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Inf w/normal ANC or Gr 1-2 neutrophils - Joint</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Inf w/normal ANC or Gr 1-2 neutrophils - Lung</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Inf w/normal ANC or Gr 1-2 neutrophils - Mid ear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness, not d/t neuropathy - body/general</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain - Buttock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain - Chest wall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain - Joint</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain - Muscle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Death - Disease progression NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Neuropathy: motor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Ocular/Visual-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginitis (not due to infection)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory - Lung</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain - Pleura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Phlebitis (including superficial thrombosis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision-blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dysphagia (difficulty swallowing)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam) - Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symp) - Oral cav</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain - Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain - Chest/thorax NOS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Inf w/normal ANC or Gr 1-2 neutrophils - UTI</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Infection-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Glucose, serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness, not d/t neuropathy - Extrem-lower</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Muscle weakness, not d/t neuropathy - body/general</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain - Bone</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain - Chest wall</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain - Extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain - Joint</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain - Muscle</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Neuropathy: motor</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain - Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Mood alteration - anxiety</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Mood alteration - depression</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory - Nose</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symp) - Pharynx</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Nasal cavity/paranasal sinus reactions</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hair loss/Alopecia (scalp or body)</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Rash: hand-foot skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lung Committee Statistician</name_or_title>
      <organization>SWOG</organization>
      <phone>206-667-4623</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

